| AJNMMI Copyright © 2011-present, All rights reserved. Published by e-Century Publishing Corporation, Madison, WI 53711, USA |
Am J Nucl Med Mol Imaging 2013;3(2):129-141
Original Article
Regional, kinetic [18F]FDG PET imaging of a unilateral Parkinsonian animal model
Matthew D Silva, Charles Glaus, Jacob Y Hesterman, Jack Hoppin, Geraldine Hill della Puppa, Timothy Kazules, Kelly M Orcutt, Mary
Germino, David Immke, Silke Miller
Departments of Research Imaging Sciences and Neuroscience, Amgen Inc., Thousand Oaks, CA and inviCRO, LLC., Boston, MA
Received August 12, 2012; Accepted February 6, 2013; Epub March 8, 2013; Published March 18, 2013
Abstract: Positron emission tomography (PET) imaging with the glucose analog 2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG) has
demonstrated clinical utility for the monitoring of brain glucose metabolism alteration in progressive neurodegenerative diseases.
We examined dynamic [18F]FDG PET imaging and kinetic modeling of atlas-based regions to evaluate regional changes in the
cerebral metabolic rate of glucose in the widely-used 6-hydroxydopamine (6-OHDA) rat model of Parkinson’s disease. Following a
bolus injection of 18.5 ± 1 MBq [18F]FDG and a 60-minute PET scan, image-derived input functions from the vena cava and left
ventricle were used with three models, including Patlak graphical analysis, to estimate the influx constant and the metabolic rate in
ten brain regions. We observed statistically significant changes in [18F]FDG uptake ipsilateral to the 6-OHDA injection in the basal
ganglia, olfactory bulb, and amygdala regions; and these changes are of biological relevance to the disease. These experiments
provide further validation for the use of [18F]FDG PET imaging in this model for drug discovery and development. (ajnmmi1208005)
Keywords: Dynamic [18F]fluoro-D-glucose positron emission tomography, 6-hydroxydopamine, brain glucose metabolism,
Parkinson’s disease
Address correspondence to: Dr. Charles Glaus, Department of Research Imaging Sciences, Amgen Inc., Thousand Oaks, CA. Tel:
805-313-5666; E-mail: cglaus@amgen.com
Original Article
Regional, kinetic [18F]FDG PET imaging of a unilateral Parkinsonian animal model
Matthew D Silva, Charles Glaus, Jacob Y Hesterman, Jack Hoppin, Geraldine Hill della Puppa, Timothy Kazules, Kelly M Orcutt, Mary
Germino, David Immke, Silke Miller
Departments of Research Imaging Sciences and Neuroscience, Amgen Inc., Thousand Oaks, CA and inviCRO, LLC., Boston, MA
Received August 12, 2012; Accepted February 6, 2013; Epub March 8, 2013; Published March 18, 2013
Abstract: Positron emission tomography (PET) imaging with the glucose analog 2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG) has
demonstrated clinical utility for the monitoring of brain glucose metabolism alteration in progressive neurodegenerative diseases.
We examined dynamic [18F]FDG PET imaging and kinetic modeling of atlas-based regions to evaluate regional changes in the
cerebral metabolic rate of glucose in the widely-used 6-hydroxydopamine (6-OHDA) rat model of Parkinson’s disease. Following a
bolus injection of 18.5 ± 1 MBq [18F]FDG and a 60-minute PET scan, image-derived input functions from the vena cava and left
ventricle were used with three models, including Patlak graphical analysis, to estimate the influx constant and the metabolic rate in
ten brain regions. We observed statistically significant changes in [18F]FDG uptake ipsilateral to the 6-OHDA injection in the basal
ganglia, olfactory bulb, and amygdala regions; and these changes are of biological relevance to the disease. These experiments
provide further validation for the use of [18F]FDG PET imaging in this model for drug discovery and development. (ajnmmi1208005)
Keywords: Dynamic [18F]fluoro-D-glucose positron emission tomography, 6-hydroxydopamine, brain glucose metabolism,
Parkinson’s disease
Address correspondence to: Dr. Charles Glaus, Department of Research Imaging Sciences, Amgen Inc., Thousand Oaks, CA. Tel:
805-313-5666; E-mail: cglaus@amgen.com
 |  |  |  |  |  |  |